Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 10, 2017 Filed Jan 12, 2017 16:31 UTC |
Cormack Scott DanielDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-003460 · doc4.xml · derivative · entry 8 Cormack Scott Daniel · CIK 0001442675 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2018-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F5 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 18:30 UTC |
Bencich JohnCFO
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-052372 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455 Underlying: Common Stock · 454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of: (i) each anniversary of August 12, 2014 and (ii) the first day thereafter during which the issuer's trading window is open. F5 · derivative.expiration_date: The RSUs expire 30 days from the date they vest. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 18:30 UTC |
Bencich JohnCFO
|
Tax withholdingCommon Stock | 149 | $3.09 | $460.41 |
DisclosureSEC source: 0001209191-17-052372 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy its income tax withholding obligations in connection with the net settlement of RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 18:30 UTC |
Bencich JohnCFO
|
Exercise / conversionCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-052372 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 18:28 UTC |
Cormack Scott DanielDirector
|
Tax withholdingCommon Stock | 1,491 | $3.09 | $4,607.19 |
DisclosureSEC source: 0001209191-17-052370 · doc4.xml · nonDerivative · entry 1 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,810 F1 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy its income tax withholding obligations in connection with the net settlement of restricted stock units reported by the reporting holder on August 3, 2017 in connection with the consummation of the merger on August 1, 2017 between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. and does not represent a sale by the reporting person. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 01:01 UTC |
JACOBS CINDYEVP, CMO
|
GrantStock Option (right to buy) · Derivative | 274,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047599 · doc4.xml · derivative · entry 3 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,000 Underlying: Common Stock · 274,000 shares Expires 2027-08-01 F5 · derivative.exercise_date: The options vest as to 25% on August 1, 2018 and thereafter in monthly installments over 36 months. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 01:01 UTC |
JACOBS CINDYEVP, CMO
|
GrantRestricted Stock Unit (RSU) · Derivative | 54,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047599 · doc4.xml · derivative · entry 2 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,800 Underlying: Common Stock · 54,800 shares Expires 2021-08-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 1, 2017 and (ii) the first day thereafter during which the issuer's trading window is open. F4 · derivative.expiration_date: The RSUs expire 30 days from the date they vest. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 01:06 UTC |
Bencich JohnCFO
|
GrantStock Option (right to buy) · Derivative | 274,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047603 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,000 Underlying: Common Stock · 274,000 shares Expires 2027-08-01 F4 · derivative.exercise_date: The options vest as to 25% on August 1, 2018 and thereafter in monthly installments over 36 months. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 01:06 UTC |
Bencich JohnCFO
|
GrantRestricted Stock Unit (RSU) · Derivative | 54,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047603 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,800 Underlying: Common Stock · 54,800 shares Expires 2021-08-01 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 1, 2017 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 9 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 8 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 454 shares Expires 2018-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F5 · derivative.exercise_date: Pursuant to the terms of the reporting holder's spouse's consulting agreement, the RSU immediately vested on August 1, 2017, in connection with the consummation of the Merger. F4 · derivative.underlying_shares: Reflects the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 852 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 7 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 852 shares Expires 2019-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F5 · derivative.exercise_date: Pursuant to the terms of the reporting holder's spouse's consulting agreement, the RSU immediately vested on August 1, 2017, in connection with the consummation of the Merger. F4 · derivative.underlying_shares: Reflects the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 6 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 284 shares Expires 2018-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F5 · derivative.exercise_date: Pursuant to the terms of the reporting holder's spouse's consulting agreement, the RSU immediately vested on August 1, 2017, in connection with the consummation of the Merger. F4 · derivative.underlying_shares: Reflects the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 852 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 5 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 852 shares Expires 2018-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the reporting holder's employment agreement, the RSUs immediately vested in full on August 1, 2017, in connection with the consummation of the Merger. F4 · derivative.underlying_shares: Reflects the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 4 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,705 shares Expires 2019-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the reporting holder's employment agreement, the RSUs immediately vested in full on August 1, 2017, in connection with the consummation of the Merger. F4 · derivative.underlying_shares: Reflects the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 568 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · derivative · entry 3 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 568 shares Expires 2018-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the reporting holder's employment agreement, the RSUs immediately vested in full on August 1, 2017, in connection with the consummation of the Merger. F4 · derivative.underlying_shares: Reflects the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionCommon Stock | 1,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · nonDerivative · entry 2 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 9,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. On August 1, 2017, the effective date of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. (the "Merger"), the closing price of Achieve Life Sciences, Inc.'s common stock was $4.576 per share, representing a closing price of $0.416 per share of Oncogenex common stock as adjusted to reflect an 11-to-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:58 UTC |
Cormack Scott DanielDirector
|
Exercise / conversionCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047593 · doc4.xml · nonDerivative · entry 1 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. On August 1, 2017, the effective date of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. (the "Merger"), the closing price of Achieve Life Sciences, Inc.'s common stock was $4.576 per share, representing a closing price of $0.416 per share of Oncogenex common stock as adjusted to reflect an 11-to-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:56 UTC |
PARKER H STEWARTDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047590 · doc4.xml · derivative · entry 2 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:54 UTC |
MATTINGLY MARTIN ADirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047588 · doc4.xml · derivative · entry 2 MATTINGLY MARTIN A · CIK 0001265782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:46 UTC |
Clarke AnthonyDirector · Chief Scientific Officer
|
GrantCommon Stock | 6,364,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047582 · doc4.xml · nonDerivative · entry 3 Clarke Anthony · CIK 0001713368 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 6,364,335 F1 · price: Received in exchange for 1,500 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:46 UTC |
Clarke AnthonyDirector · Chief Scientific Officer
|
GrantCommon Stock | 4,242,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047582 · doc4.xml · nonDerivative · entry 2 Clarke Anthony · CIK 0001713368 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,242,890 F2 · price: Received in exchange for 1,000 common shares of Achieve pursuant to the Merger between OncoGenex and Achieve. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:46 UTC |
Clarke AnthonyDirector · Chief Scientific Officer
|
GrantCommon Stock | 6,364,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047582 · doc4.xml · nonDerivative · entry 1 Clarke Anthony · CIK 0001713368 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,364,335 F1 · price: Received in exchange for 1,500 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:52 UTC |
MOYES JAY MDirector
|
GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047586 · doc4.xml · derivative · entry 1 MOYES JAY M · CIK 0001191062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2027-08-01 F1 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from August 1, 2017. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:49 UTC |
Joseph DonaldDirector
|
GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-047584 · doc4.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2027-08-01 F1 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from August 1, 2017. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:43 UTC |
Stewart Richard AlistairDirector · President & CEO
|
GrantCommon Stock | 848,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047575 · doc4.xml · nonDerivative · entry 2 Stewart Richard Alistair · CIK 0001713369 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 848,578 F2 · price: Received in exchange for 200 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 4, 2017 00:43 UTC |
Stewart Richard AlistairDirector · President & CEO
|
GrantCommon Stock | 22,487,319 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047575 · doc4.xml · nonDerivative · entry 1 Stewart Richard Alistair · CIK 0001713369 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,487,319 F1 · price: Received in exchange for 4,300 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 16:53 UTC Amendment |
Stewart Richard AlistairDirector · Chairman & CEO
|
GrantCommon Stock | 176,418 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048530 · doc4a.xml · nonDerivative · entry 3 Stewart Richard Alistair · CIK 0001713369 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Ricanto Limited Disclosed balance after: 176,418 F3 · shares: This amended Form 4 is filed to include the number of common shares received in exchange for 491 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. F3 · price: This amended Form 4 is filed to include the number of common shares received in exchange for 491 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. F4 · ownership.nature: The reporting holder is a principal owner of Ricanto Limited. Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 16:53 UTC Amendment |
Stewart Richard AlistairDirector · Chairman & CEO
|
GrantCommon Stock | 71,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048530 · doc4a.xml · nonDerivative · entry 2 Stewart Richard Alistair · CIK 0001713369 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 71,861 F2 · shares: This amended Form 4 is filed to correct the number of common shares received in exchange for 200 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. F2 · price: This amended Form 4 is filed to correct the number of common shares received in exchange for 200 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 16:53 UTC Amendment |
Stewart Richard AlistairDirector · Chairman & CEO
|
GrantCommon Stock | 1,950,309 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048530 · doc4a.xml · nonDerivative · entry 1 Stewart Richard Alistair · CIK 0001713369 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950,309 F1 · shares: This amended Form 4 is filed to correct the number of common shares received in exchange for 5,428 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). F1 · price: This amended Form 4 is filed to correct the number of common shares received in exchange for 5,428 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 18:18 UTC Amendment |
Clarke AnthonyDirector · President & CSO
|
GrantCommon Stock | 176,418 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048552 · doc4a.xml · nonDerivative · entry 4 Clarke Anthony · CIK 0001713368 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Ricanto Limited Disclosed balance after: 176,418 F4 · price: This amended Form 4 is filed to include the number of common shares received in exchange for 491 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. F5 · ownership.nature: The reporting holder is a principal owner of Ricanto Limited. Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 18:18 UTC Amendment |
Clarke AnthonyDirector · President & CSO
|
GrantCommon Stock | 538,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048552 · doc4a.xml · nonDerivative · entry 3 Clarke Anthony · CIK 0001713368 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 538,958 F3 · shares: This amended Form 4 is filed to correct the number of common shares received in exchange for 1,500 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. F3 · price: This amended Form 4 is filed to correct the number of common shares received in exchange for 1,500 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 18:18 UTC Amendment |
Clarke AnthonyDirector · President & CSO
|
GrantCommon Stock | 359,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048552 · doc4a.xml · nonDerivative · entry 2 Clarke Anthony · CIK 0001713368 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 359,305 F2 · shares: This amended Form 4 is filed to correct the number of common shares received in exchange for 1,000 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. F2 · price: This amended Form 4 is filed to correct the number of common shares received in exchange for 1,000 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 01, 2017 Filed Aug 11, 2017 18:18 UTC Amendment |
Clarke AnthonyDirector · President & CSO
|
GrantCommon Stock | 550,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048552 · doc4a.xml · nonDerivative · entry 1 Clarke Anthony · CIK 0001713368 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,455 F1 · shares: This amended Form 4 is filed to correct the number of common shares received in exchange for 1,532 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). F1 · price: This amended Form 4 is filed to correct the number of common shares received in exchange for 1,532 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split"). Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 19:15 UTC Amendment |
MOYES JAY MDirector
|
GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052399 · doc4a.xml · derivative · entry 1 MOYES JAY M · CIK 0001191062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. F2 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from August 1, 2017. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 19:04 UTC Amendment |
PARKER H STEWARTDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052386 · doc4a.xml · derivative · entry 1 PARKER H STEWART · CIK 0001217456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 19:09 UTC Amendment |
Joseph DonaldDirector
|
GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052393 · doc4a.xml · derivative · entry 1 Joseph Donald · CIK 0001319460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. F2 · derivative.exercise_date: The options vest in monthly installments over 36 months commencing one month from August 1, 2017. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 19:01 UTC Amendment |
MATTINGLY MARTIN ADirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052382 · doc4a.xml · derivative · entry 1 MATTINGLY MARTIN A · CIK 0001265782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 18:46 UTC Amendment |
Cormack Scott DanielDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052377 · doc4a.xml · derivative · entry 1 Cormack Scott Daniel · CIK 0001442675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 18:52 UTC Amendment |
JACOBS CINDYEVP, CMO
|
GrantStock Option (right to buy) · Derivative | 274,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052380 · doc4a.xml · derivative · entry 1 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,000 Underlying: Common Stock · 274,000 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. F2 · derivative.exercise_date: The options vest as to 25% on August 1, 2018 and thereafter in monthly installments over 36 months. Read SEC document |
| August 01, 2017 Filed Sep 12, 2017 18:43 UTC Amendment |
Bencich JohnCFO
|
GrantStock Option (right to buy) · Derivative | 274,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-17-052375 · doc4a.xml · derivative · entry 1 Bencich John · CIK 0001477056 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,000 Underlying: Common Stock · 274,000 shares Expires 2027-08-01 F1 · derivative.exercise_price: This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant. All other terms remain the same. F2 · derivative.exercise_date: The options vest as to 25% on August 1, 2018 and thereafter in monthly installments over 36 months. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:39 UTC |
Cormack Scott DanielDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039846 · doc4.xml · derivative · entry 5 Cormack Scott Daniel · CIK 0001442675 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually each anniversary of June 12, 2014, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:39 UTC |
Cormack Scott DanielDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039846 · doc4.xml · derivative · entry 4 Cormack Scott Daniel · CIK 0001442675 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2018-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually each anniversary of June 12, 2014, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:39 UTC |
Cormack Scott DanielDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039846 · doc4.xml · nonDerivative · entry 3 Cormack Scott Daniel · CIK 0001442675 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 89,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:39 UTC |
Cormack Scott DanielDirector · President and CEO
|
Tax withholdingCommon Stock | 4,472 | $0.36 | $1,609.92 |
DisclosureSEC source: 0001209191-17-039846 · doc4.xml · nonDerivative · entry 2 Cormack Scott Daniel · CIK 0001442675 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,953 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs and does not represent a sale by the reporting person. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:39 UTC |
Cormack Scott DanielDirector · President and CEO
|
Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039846 · doc4.xml · nonDerivative · entry 1 Cormack Scott Daniel · CIK 0001442675 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:30 UTC |
JACOBS CINDYEVP, CMO
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039835 · doc4.xml · derivative · entry 3 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually each anniversary of June 12, 2014, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:30 UTC |
JACOBS CINDYEVP, CMO
|
Tax withholdingCommon Stock | 1,633 | $0.36 | $587.88 |
DisclosureSEC source: 0001209191-17-039835 · doc4.xml · nonDerivative · entry 2 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,726 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs and does not represent a sale by the reporting person. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:30 UTC |
JACOBS CINDYEVP, CMO
|
Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039835 · doc4.xml · nonDerivative · entry 1 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 16:48 UTC |
JACOBS CINDYEVP, CMO
|
Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 4,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-003464 · doc4.xml · derivative · entry 5 JACOBS CINDY · CIK 0001229762 · EVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 4,687 shares Expires 2019-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F6 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.